<DOC>
	<DOCNO>NCT02408458</DOCNO>
	<brief_summary>This study conduct gather long-term data performance Miromatrix Biological Mesh .</brief_summary>
	<brief_title>Miromatrix Biological Mesh Ventral Hernia Repair</brief_title>
	<detailed_description>Miromatrix Medical Inc. develop new biologic mesh , call MIROMESH® . MIROMESH receive FDA 510 ( k ) clearance indication reinforcement soft tissue March 31 , 2014 K134033 . Miromatrix Biologic Mesh non cross-link , acellular surgical mesh derive highly vascularized porcine liver . This study serve provide clinician high-quality clinical data order provide high degree confidence select MIROMESH ventral hernia repair .</detailed_description>
	<mesh_term>Hernia</mesh_term>
	<mesh_term>Hernia , Ventral</mesh_term>
	<criteria>18 80 year old day study enrollment ventral incisional hernia great 9 cm2 physician anticipate ability achieve midline fascia closure follow retrorectus repair/component separation hernia classify CDC class 1 2 preoperatively able willing sign consent form comply study visit procedure commit nonsmoking least 4 week prior procedure sensitivity porcine material schedule concomitant procedure wound classify clean immunocompromised risk immunosuppression ( i.e . HIV positive , experience organ rejection , recent anticipate chemotherapy recipient ) determine Investigator BMI ≥40 A1C level ≥10.0 participate another clinical study cirrhosis , and/or ascites diagnose collagen vascular disorder American Society Anesthesiology ( ASA ) Class 4 5 allergic tetracycline kanacmycin life expectancy le 2 year time enrollment condition opinion Investigator would preclude use study device , preclude subject complete followup requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>